SCHEMBL212820

SCHEMBL212820

COC(=O)c1ccc2c(C=O)c[nH]c2c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLG P00747 1/20 0.61
PLAU P00749 1/20 0.61
ALDH1A1 P00352 3/20 0.60
KDM4E B2RXH2 1/20 0.60
MAPT P10636 1/20 0.60
NPC1 O15118 1/20 0.59
CYP2A6 P11509 2/20 0.53
KIF11 P52732 1/20 0.51
ASH1L Q9NR48 1/20 0.51
CYP1A2 P05177 1/20 0.49
CYP2C19 P33261 1/20 0.49
PIM1 P11309 1/20 0.48
PIM3 Q86V86 1/20 0.48
PARP1 P09874 1/20 0.48
NR4A2 P43354 2/20 0.48
GPR84 Q9NQS5 1/20 0.47
ERN1 O75460 2/20 0.47
RAB9A P51151 1/20 0.47
IMPDH2 P12268 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2161358 0.88 ALDH1A1 (0.60) PLGPLAUALDH1A1KDM4EMAPT
SCHEMBL8646085 0.85 NPC1 (0.53) PLGPLAUALDH1A1KDM4EMAPT
SCHEMBL29958268 0.85 IMPDH2 (0.59) PLGPLAUALDH1A1KDM4EMAPT
SCHEMBL7471673 0.83 NPC1 (0.54) PLGPLAUALDH1A1KDM4EMAPT
SCHEMBL7419015 0.83 NPC1 (0.54) PLGPLAUALDH1A1KDM4EMAPT
SCHEMBL7471670 0.83 NPC1 (0.54) PLGPLAUALDH1A1KDM4EMAPT
SCHEMBL7420992 0.83 NPC1 (0.54) PLGPLAUALDH1A1KDM4EMAPT
SCHEMBL2219992 0.81 PLG (0.68) PLGPLAUALDH1A1KDM4EMAPT
SCHEMBL29951912 0.81 PLG (0.68) PLGPLAUALDH1A1KDM4EMAPT
SCHEMBL18918116 0.81 NPC1 (0.52) PLGPLAUALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-3058968-A None JP disclosed
CN-119907798-A Novel substituted 2,3,4, 9-tetrahydro-1H-pyrido [3,4-B ] indolecarboxylic acid derivatives, process for their preparation and their therapeutic use 赛诺菲 2025-04-29 CN disclosed
US-12012411-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-18 US disclosed
CN-115260180-B Triazole condensed ring derivative, pharmaceutical composition, preparation method and application thereof 长春金赛药业有限责任公司 2024-05-28 CN disclosed
WO-2024042163-A1 NOVEL SUBSTITUTED 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE CARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2024-02-29 WO disclosed
WO-2024042163-A1 NOVEL SUBSTITUTED 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE CARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2024-02-29 WO disclosed
WO-2024039861-A1 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER OLEMA PHARMACEUTICALS, INC. (US) 2024-02-22 WO disclosed
CN-110526854-B Alpha, beta-unsaturated ketone derivative, preparation method and application thereof as medicine 宁夏医科大学 2023-12-15 CN disclosed
CN-114213396-B Indole-2-ketone compound and preparation method and application thereof 深圳市乐土生物医药有限公司 2023-03-24 CN disclosed
CN-115260180-A Triazole fused ring containing derivative, pharmaceutical composition, preparation method and application thereof 长春金赛药业有限责任公司 2022-11-01 CN disclosed
EP-0934307-A1 SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE RHONE-POULENC RORER LIMITED (GB) 1999-08-11 EP disclosed
CN-1187812-A Indole derivatives as CGMP-PDE inhibitors FUJISAWA PHARMACEUTICAL CO (JP) 1998-07-15 CN disclosed
WO-1998005327-A1 SUBSTITUTED AROMATIC COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1998-02-12 WO disclosed
EP-0820441-A1 INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-01-28 EP disclosed
WO-1997048697-A1 SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE RHONE-POULENC RORER LIMITED (GB) 1997-12-24 WO disclosed
WO-1996032379-A1 INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-10-17 WO disclosed
US-5332755-A Leukotriene antagonists as antiinflammatory agents and antiallergens BAYER AKTIENGESELLSCHAFT (DE) 1994-07-26 US disclosed
US-5118700-A Leukotriene antagonist BAYER AKTIENGESELLSCHAFT (DE) 1992-06-02 US disclosed
JP-H0358968-A NOVEL INDOLE DERIVATIVE, ITS PREPARATION AND ITS USE AS DRUG BAYER AG 1991-03-14 JP disclosed
EP-0409027-A1 Indole derivatives, process for their preparation and their use in pharmaceuticals BAYER AG (DE) 1991-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12012411-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 PLG 3603/4885PLAU 3410/4885ALDH1A1 4277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.